Copy number alterations have long been an identified feature of several cancers; prominent examples include ERBB2 (HER2) amplification, observed in nearly 20% of breast cancer cases [72], and MYCN amplification, estimated in 25% of neuroblastoma cases [73]. This evidence concerns the gene ERBB2 and breast carcinoma.